Adaption of DOTA-PRIT to image-guided α-particle therapy with 203Pb/212Pb

Lead-212 (212Pb) is a very promising α-emitting radionuclide for targeted radiotherapy (t1/2 = 10.6 h) with an elementally matched γ-emitting isotope lead-203 (203Pb) (t1/2 = 52 h) that can be used as an imaging surrogate. We are currently exploring candidate 203Pb/212Pb radiohaptens, and establishing anti-tumor efficacy with DOTA-ligand bound radionucleide based pretargeted radioimmunotherapy (DOTA-PRIT) in immunocompromised mice bearing established human xenograft tumors.